Founded with the mission to improve global health, General Fluidics focuses on making high-quality blood diagnostics more accessible. The company develops innovative in vitro diagnostic tools, including its flagship Axess™ point-of-care testing platform, which performs comprehensive blood and urine tests. Utilizing a patented hybrid hardware architecture, fluidics, and optoelectronic technologies, General Fluidics aims to deliver complete diagnostic information sets directly at the point of care, bridging the gap between patients, clinicians, and reliable diagnostic data.

General Fluidics has attracted notable investors and industry experts who believe in its transformative potential. The company has achieved significant milestones, including the successful development and deployment of its Axess™ platform, which has been well-received in clinical settings for its accuracy and convenience. By creating an entirely new category of blood testing technology, General Fluidics is making a substantial impact on the healthcare industry, enhancing the speed and quality of diagnostics available at the point of care.